Post-COVID syndrome remains poorly studied in children and adolescents. Here, we aimed to investigate the prevalence and risk factors of pediatric post-COVID in a population-based sample, stratifying by serological status. Children from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), aged 6 months to 17 years, were tested for anti-SARS-CoV-2 N antibodies (December 2021-February 2022) and parents filled in a questionnaire on persistent symptoms in their children (lasting over 12 weeks) compatible with post-COVID. Of 1034 children tested, 570 (55.1%) were seropositive. The sex- and age-adjusted prevalence of persistent symptoms among seropositive children was 9.1% (95%CI: 6.7;11.8) and 5.0% (95%CI: 3.0;7.1) among seronegatives, with an adjusted prevalence difference (ΔaPrev) of 4.1% (95%CI: 1.1;7.3). Stratifying per age group, only adolescents displayed a substantial risk of having post-COVID symptoms (ΔaPrev = 8.3%, 95%CI: 3.5;13.5). Identified risk factors for post-COVID syndrome were older age, having a lower socioeconomic status and suffering from chronic health conditions, especially asthma. Our findings show that a significant proportion of seropositive children, particularly adolescents, experienced persistent COVID symptoms. While there is a need for further investigations, growing evidence of pediatric post-COVID urges early screening and primary care management.
Background The medium-term impact of the COVID-19 pandemic on the wellbeing of children and adolescents remains unclear. More than 2 years into the pandemic, we aimed to quantify the frequency and determinants of having been severely impacted by the COVID-19 pandemic and estimate its impact on health-related quality of life (HRQoL) and mental health. Methods Data was drawn from a population-based cohort of children and adolescents, recruited between December 2021 and June 2022, in Geneva, Switzerland. The Coronavirus impact scale was used to assess the multidimensional impact of the pandemic on children through parent’s report. A score higher than one standard deviation above the mean was deemed a severe impact. Parents additionally reported about their offspring HRQoL and mental health with validated scales. Determinants of having been severely impacted were assessed with logistic models, as were the associations between having experienced a severe impact and poor HRQoL or mental health. Results Out of 2101 participants aged 2–17, 12.7% had experienced a severe pandemic impact. Having a lasting health condition, a pandemic-related worsening of lifestyle habits or an unfavorable family environment were associated with having been severely impacted by the pandemic, while a previous anti-SARS-CoV-2 infection was not. Participants who had experienced a severe pandemic impact were more likely to present poor HRQoL (aOR = 3.1; 95% CI 2.3–4.4) and poor mental health (aOR = 3.9; 95% CI 2.5–6.2). Conclusion The COVID-19 pandemic may have persistent consequences on the wellbeing of children and adolescents, especially among those with health and family vulnerabilities.
Uvod: Pleurocenteza (torakocenteza) je dijagnostičko-terapijska metoda koja se koristi za dobijanje uzorka ili evakuaciju pleuralne tečnosti. Palijativna pleurocenteza se izvodi u cilju evakuacije malignog izliva koji je znak uznapredovalog stadijuma maligne bolesti. Cilj: Prikazati primenu metode palijativne pleurocenteze i odnos broja pacijenata sa malignim pleuralnim izlivom u zavisnosti od porekla primarnog tumora u jednogodišnjem periodu. Pacijenti i metode: U periodu od 01. 08. 2014. do 01. 08. 2015. godine na hirurškom odeljenju Opšte bolnice u Kikindi primenjena je palijativna pleurocenteza kod 23 pacijenta, prosečne starosti 68,6 godina. Dijagnoza je prethodno postavljena na osnovu kliničkog pregleda i rendgenskog snimka pluća. Za punkciju je korišćen set za jednokratnu upotrebu Pleurofix® Nr.1, kompanije B. Braun. Kod svih pacijenata pleurocenteza je izvedena u sedećem položaju, u lokalnoj anesteziji (2% lidokain), u VII ili VIII međurebarnom prostoru, u zadnjoj aksilarnoj liniji, tik uz gornju ivicu donjeg rebra. Za statističku analizu korišćen je χ 2-test. Rezultati: Palijativna pleurocenteza je primenjena kod 14 (60,87%) žena i 9 (39,13%) muškaraca (χ 2 =1,08; p>0,05). Ukupno je urađeno 38 pleurocenteza, prosečno po pacijentu 1,65. Jedna pleurocenteza je urađena kod 18 (78,25%) pacijenata, a dve ili više kod 5 (21,75%) pacijenata (χ 2 =30,21; p<0,01). Dve pleurocenteze su urađene kod 1 (4,35%), tri kod 2 (8,7%) i šest kod 2 (8,7%) pacijenta. Sa desne strane je urađena kod 14 (60,87%), a sa leve kod 6 (26,09%) pacijenata (χ 2 =8,43; p<0,05). Obostrano je urađena kod 3 (13,04%) pacijenta. Etiološki, karcinom pluća je bio uzrok kod 9 (39,13%), dojke kod 4 (17,39%), GIT-a kod 3 (13,04%), UGT-a kod 3 (13,04%), dok je kod 4 (17,39%) pacijenta ostalo nepoznato mesto primarnog tumora. Zaključak: Maligni pleuralni izliv se najčešće javlja kod pacijenata obolelih od karcinoma pluća i dojke. Češće je lokalizovan na desnoj strani. Kod značajnog broja pacijenata ostaje nepoznato mesto primarnog tumora. Palijativna pleurocenteza ima ulogu u trenutnom ublažavanju simptoma. U cilju adekvatnog tretmana potrebno je konsultovati grudnog hirurga. Ključne reči: Maligni pleuralni izliv; pleurocenteza; torakocenteza.
OPŠTA BOLNICA KIKINDA / GENERAL HOSPITAL KIKINDA Sažetak:Uvod: Primarni retroperitonealni tumori su veoma retki i čine 0,05-0,2% svih tumora. Solitarni fibrozni tumori čine oko 0,03% svih tumora, odnosno oko 3% tumora mekih tkiva. Ovi tumori se retko javljaju u retroperitoneumu i često recidiviraju. U periodu od 1990. do 2010. godine u literaturi je opisano 57 slučajeva. Prikaz pacijenata: Osoba ženskog pola, 56 godina starosti, sa tupim bolom u trbuhu i palpabilnom tumefakcijom u donjem levom kvadrantu. Laboratorijske analize, uključujući i tumor markere, i kolonoskopija su bili uredni. Na ultrazvučnom pregledu abdomena i MSCT-u viđena je velika, solidna tumorska masa u retroperitoneumu koja je potiskivala levi kolon i tanko crevo. Pacijentkinja je operisana laparotomijom, te je tumor uklonjen u celosti. Odstranjeni tumor je bio inkapsuliran, elastične i čvrste konzistencije, dimenzija 160x120x80mm, težine 580g. Patohistološka i imunohistohemijska ispitivanja su pokazala da se radi o benignom solitarnom fibroznom tumoru. Postoperativni tok je bio normalan i protekao je bez komplikacija, a pacijentkinja je otpuštena kući šestog postoperativnog dana. Zaključak: Hirurško lečenje predstavlja zlatni standard u lečenju ovih tumora. Zbog sklonosti ka recidiviranju, potrebno je dugoročno praćenje i kontrolisanje ovih pacijenata. Ključne reči: solitarni fibrozni tumor, retroperitoneum, hirurško lečenje. Summary:Introduction: Primary retroperitoneal tumours are rare (0.05-0.2% of all tumours). Solitary fibrous tumour accounts for 0.03% of all neoplasms and 3.0% of all soft tissue tumours. Retroperitoneal solitary fibrous tumour occurs infrequently and is often recidivous. Between 1990 and 2010, 57 cases were reported in literature. Case report: A 56 year old female presented with abdominal dull pain and palpable mass in the left lower quadrant. The laboratory studies including tumour markers and colonoscopy were negative. Imaging abdominal ultrasound and MSCT scan showed a large solid tumour located in the retroperitoneum compressing the left colon and the small bowel. A laparotomy was performed and the tumour was excised in total. The excised tumour was an encapsulated, elastic and hard, 160x120x80mm in size, 580 g in weight. Histopathological and immunohistochemical examinations disclosed a benign solitary fibrous tumour. Postoperative evolution of the patient was uneventful and she was discharged from hospital 6 days after the surgical procedure. Conclusion: Surgical treatment is the gold standard in the treatment of these tumours. Because of the tendency to recur, it is necessary to have long-term monitoring and examination of these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.